共付额和经济援助
AmeriPharma® 特药药房减轻了患者及其家人的经济负担
-
先进的软件可以定位资金来源，为您匹配高额的基金会项目
-
我们的一位共付额援助专家将协助您完成申请流程
-
自动更新信息将发送给您和您的医生，告知您资金状况
Jaypirca 是什么？
Jaypirca is an anticancer medication, also known by the name of the active component it contains: pirtobrutinib. This medication was recently granted accelerated approval by the FDA for treating refractory or relapsed mantle cell lymphoma (MCL), a form of non-Hodgkin’s lymphoma (NHL), in adult patients. As an accelerated approval medication, Jaypirca fills a medical need for MCL that other medication therapies currently do not meet. However, in order to obtain regular FDA approval, the drug company must complete clinical trials to further confirm the clinical benefit of this medication.
Jaypirca (pirtobrutinib) belongs to the drug class called “BTK inhibitors,” which block the activity of the BTK enzyme and inhibit the abnormal growth of B-cells in MCL. Jaypirca is unique in that it is a non-covalent inhibitor, whereas other treatments for MCL on the market are covalent inhibitors. As a non-covalent inhibitor, Jaypirca targets specific BTK mutations that are becoming resistant to the covalent inhibitors.
Jaypirca 用于治疗什么？
Jaypirca 用于治疗成年患者的难治性或复发性套细胞淋巴瘤 (MCL)，这些患者的癌症已复发或对之前的治疗失去反应，并且已接受过至少两种或两种以上先前治疗，包括共价 BTK 药物。
套细胞淋巴瘤 (MCL) 是一种影响淋巴系统的血癌，被认为是由 B 细胞（一种帮助人体抵抗感染的白细胞）发生的基因突变或改变引起的。在 MCL 中，这些基因改变导致 B 细胞不受控制地生长和分裂，从而导致淋巴系统中形成大量异常细胞（肿瘤）。MCL 通常发生在淋巴结中，但也可能扩散到其他器官，例如骨髓、脾脏和胃肠道。
MCL is a relatively rare type of non-Hodgkin’s lymphoma (NHL), accounting for about 6% of all NHL cases.
共付额和经济援助
AmeriPharma® 特药药房减轻了患者及其家人的经济负担
-
先进的软件可以定位资金来源，为您匹配高额的基金会项目
-
我们的一位共付额援助专家将协助您完成申请流程
-
自动更新信息将发送给您和您的医生，告知您资金状况
Jaypirca Dosing Information
Jaypirca is currently available in 50 mg and 100 mg tablets. Jaypirca is well tolerated and is only available with a doctor’s prescription.
The initial recommended dose for adults with MCL is 200 mg (two 100 mg tablets) once a day. However, the dosage of Jaypirca can be adjusted according to the patient’s health status. For example, if you have severe kidney impairment, take certain medications, or if you are experiencing an adverse reaction from your current dose of Jaypirca, your doctor may change the dose to decrease side effects.
过量
避免服用双倍剂量的 Jaypirca 来弥补漏服剂量。如果您漏服剂量超过 12 小时，请跳过该剂量，并按照医生规定的常规时间服用下一剂。
Jaypirca Side Effects
临床报告显示，≥15% 的 MCL 患者服用 Jaypirca 后可能出现的常见副作用包括：
- 疲倦或疲劳
- 腹泻
- 肺炎
- 肌肉骨骼疼痛（肌肉、骨骼和关节疼痛）
- 肿胀和瘀伤
- 呼吸短促（呼吸困难）
此外，不太常见或罕见的不良反应包括：
- 感染（包括细菌、病毒或真菌感染）
- 出血问题（包括尿血、血便血或呕血）
- Decreased blood cell counts (including neutropenia, anemia, and thrombocytopenia)
- Atrial fibrillation and flutter (abnormal heart beats or chest discomfort)
- 第二原发性恶性肿瘤（皮肤或其他器官的新癌症）
接受保险
我们接受 Medicare、跨州 Medicaid、Medi-Cal、Blue Shield 以及大多数私人保险。请致电我们，了解更多您的保险信息。
